- Company
- PCSK9i Praluent can be prescribed after 5 years of approval
- by Eo, Yun-Ho Jan 19, 2022 06:07am
- Praluent can be prescribed at general hospitals. As a result, practical competition for PCSK9 inhibitors began five years after domestic approval. According to related industries, Sanofi-Aventis Korea's Praluent (Alirocumab) passed the Drug Committee of medical institutions such as Seoul National University Bundang Hospital, Gangnam Sever
- Company
- 3 Korean companies accelerate Stelara biosimilar development
- by Ji Yong Jun Jan 19, 2022 06:06am
- Korean companies are rushing to get a share of Stelara’s autoimmune disease treatment market that brings in &8361;9 trillion in annual sales. Samsung Bioepis, which had been late in starting the development of Stelara biosimilars than its competitors like Dong-A ST and Celltrion, completed patient recruitment for its Phase III trial and pu
- Company
- Exporting medicines to North America ↑ 2.6 times in 2 years
- by Kim, Jin-Gu Jan 19, 2022 06:06am
- Exports of domestic drugs hit an all-time high last year, especially exports to the North American market surged, the report showed. Exports to the U.S. and Canada have increased 2.6 times in two years. Germany is still the largest exporter, but it is estimated to have decreased slightly compared to last year. In addition, exports of medic
- Company
- Pharma exports exceed ₩9 trillion in 2021
- by Kim, Jin-Gu Jan 18, 2022 06:05am
- Pharmaceutical exports in Korea have exceeded &8361;9 trillion last year. With exports increasing around biopharmaceuticals, sales of the drugs increased over 2.2 times over the past 2 years. Imports have also reached record-high, influenced by the increased import of Pfizer and Moderna’s COVID-19 vaccines. On the other hand, the export of
- Company
- First PIK3CA-targeting ‘Piqray’ lands in general hospitals
- by Eo, Yun-Ho Jan 17, 2022 05:51am
- ‘Piqray,’ the first targeted anticancer drug that targets the PIK3CA gene, may now be prescribed at general hospitals. According to industry sources, Novartis Korea’s ‘Piqray (alpelisib)’ passed the drug committee (DC) reviews of 2 of the ‘Big 5’ hospitals in Korea - the Seoul Samsung Medical Center, and Seoul Asan Medical Center.
- Company
- Shortening the completion of Samsung Biologics plant 4
- by Kim, Jin-Gu Jan 17, 2022 05:51am
- Samsung Biologics announced that it will start partial operation within this year in connection with its fourth plant currently under construction. It also introduced that it has already won orders for consignment production from three global pharmaceutical companies. John Lim, CEO of Samsung BioLogics, made the remarks at a press conference
- Company
- Korean companies' progress in developing COVID-19 treatment
- by Moon, sung-ho Jan 17, 2022 05:51am
- News of the decision to introduce Pfizer’s oral COVID-19 treatment ‘Paxlovid’ in Korea from earlier this year has increased interest in the progress made in the development of oral COVID-19 treatments at Korean pharmaceutical companies. The interest in when the homegrown oral COVID-19 treatments will be commercialized was triggered by the
- Company
- ₩200 bil schizophrenia treatment market is changing
- by Kim, Jin-Gu Jan 14, 2022 05:50am
- Change is in the air in the schizophrenia treatment market that was once led by global pharmaceutical companies such as Otsuka Pharmaceutical and Janssen. Domestic companies are acquiring rights of originals and introducing new products to chase the multinational leaders in the market. In response to the change, the global pharmaceutical com
- Company
- One clinical trial of NeoImuneTech's new immuno-cancer drug
- by Ji Yong Jun Jan 14, 2022 05:50am
- NeoImuneTech has suspended one clinical trial for the treatment of COVID-19 of NT-I7 (efineptakin alfa), which is being developed as a new immuno-cancer drug. According to ClinicalTrials.gov operated by NIH in the U.S. on the 12th, it was confirmed that NeoImuneTech withdrew one phase 1 clinical trial related to NT-I7 in the second half of la
- Company
- SK Bioscience, speeding up its development of COVID Vaccine
- by Kim, Jin-Gu Jan 13, 2022 06:05am
- SK Bioscience is speeding up the commercialization of its own COVID-19 vaccine. In particular, it is predicted that the approval of the Novavax vaccine will have a positive effect at a time when the GBP510 is aimed at licensing items in the first half of this year. On the 12th, the MFDS approved Nuvaxovid PFS, NovaVax's COVID-19 vaccine. T
